Summary
The construction of a composite effectiveness measure was explored using clinical data collected routinely in trials of drug therapies for asthma. The measure is the episode-free day (EFD), where an ‘episode’ is either an asthma attack, the need for rescue medication, sleep disturbance caused by asthma, or an adverse event. The EFD measure was used in a retrospective cost-effectiveness analysis of a previous Phase III controlled clinical trial of formoterol versus salbutamol, in which 145 patients with bronchial asthma were randomised to receive maintenance therapy with either inhaled formoterol or inhaled salbutamol over a 12-week period. Average and incremental cost-effectiveness ratios were assessed for the 2 drugs in terms of the total expected cost of drug plus rescue therapy, and EFD rates. The analysis suggests that, with relatively little addition to clinical data collection, economically and clinically meaningful composite measures can be constructed to assist in making cost-effectiveness comparisons between alternative asthma therapies.
Similar content being viewed by others
References
Brazier JE, Harper R, Jones NMB, O’Cathian AO, Thomas KJ, et al. Validating the SF-36 health survey Questionnaire: new outcome measure for primary care. British Medical Journal 305: 160–164, 1992
Bryan S, Buxton MJ. Economic evaluation of treatments for respiratory disease. PharmacoEconomics 2: 207–218, 1992
Burney PGJ. Strategy for asthma. British Medical Journal 303: 571–573, 1991
Burr ML, Butland BK, King S, Vaughan-Williams E. Changes in asthma prevalence in two surveys 15 years apart. Archives of Disease in Childhood 64: 1452–1456, 1989
Buxton MJ. Economic evaluation studies in respiratory medicine. Respiratory Medicine 85: 43–46, 1991
Drummond MF, Davies L. Economic analysis alongside clinical trials. International Journal of Technology Assesment in Health Care 7: 561–573, 1991
Hunt SM, McEwen J, McKenna SP. Measuring health status. Croom Helm, Beckenham, 1986
Hyland ME, Coward G, Upchurch F, Jones KP. Asthma specific quality of life scale in the study of salmeterol hydroxynaphthoate. British Journal of General Practice 41: 214–215, 1991a
Hyland ME, Finnis S, Irvine SH. A scale for assessing quality of life in adult asthma sufferers. Journal of Psychosomatic Research 35: 99–110, 1991b
Juniper EF, Guyatt GH, Epstein RS, Ferie PJ, Jaeschke R, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 47: 76–83, 1992
Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. American Review of Respiratory Disease 144: 622–625, 1991
Marks G, Dunn SM, Woolcock AJ. A scale for the measurement of quality of life in adults with asthma. Journal of Clinical Epidemiology 45: 461–472, 1992
Rees J. β2-agonists and asthma still the mainstay of symptomatic treatment. British Medical Journal 302: 1166–1167, 1991
Rutten-Van Mölken MPMH, Van Doorslaer EKA, Rutten FFH. Economic appraisal of asthma and COPD care: a literature review 1980–1991. Social Science and Medicine 35: 161–175, 1992
Ware JE, Donald Sherbourne CD. The MOS 36-item Short Form Health Survey (SF-36). 1. Conceptual framework and item selection. Medical Care 30: 473–483, 1992
Weaving PG. Salmeterol therapy in mild asthma. British Journal of General Practice 41: 346, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sculpher, M.J., Buxton, M.J. The Episode-Free Day as a Composite Measure of Effectiveness. PharmacoEconomics 4, 345–352 (1993). https://doi.org/10.2165/00019053-199304050-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199304050-00005